Tikun Therapeutics

Executive Summary

Tikun Therapeutics is a US-based public benefit corporation solely dedicated to developing treatments for Familial Dysautonomia (FD), an ultra-rare, progressive genetic disorder with no approved therapies. Since its founding in 2018, the company has advanced a lead small-molecule candidate designed to address the underlying genetic defect. With a mission-driven approach, Tikun commits to ensuring low-cost access to any approved therapy. Although still in early stages, the company's singular focus and strong commitment to the FD community position it as a key player in this underserved area. Near-term milestones include completing preclinical studies and initiating first-in-human trials.

Upcoming Catalysts (preview)

• Q4 2026IND Filing for Lead Candidate60% success
• Q2 2027Initiation of Phase 1 Clinical Trial50% success
• Q4 2026FDA Orphan Drug Designation80% success